These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23529930)

  • 41. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.
    Kottakis F; Polytarchou C; Foltopoulou P; Sanidas I; Kampranis SC; Tsichlis PN
    Mol Cell; 2011 Jul; 43(2):285-98. PubMed ID: 21777817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
    Romanchikova N; Trapencieris P
    Anticancer Res; 2019 Aug; 39(8):4179-4184. PubMed ID: 31366503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
    Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
    BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
    Ougolkov AV; Bilim VN; Billadeau DD
    Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
    Riquelme E; Suraokar M; Behrens C; Lin HY; Girard L; Nilsson MB; Simon G; Wang J; Coombes KR; Lee JJ; Hong WK; Heymach J; Minna JD; Wistuba II
    Clin Cancer Res; 2014 Jul; 20(14):3849-61. PubMed ID: 24850841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
    Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
    Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
    Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
    Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
    Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
    Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
    PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
    Zhang Y; Tong T
    Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.
    Banerjee R; Mani RS; Russo N; Scanlon CS; Tsodikov A; Jing X; Cao Q; Palanisamy N; Metwally T; Inglehart RC; Tomlins S; Bradford C; Carey T; Wolf G; Kalyana-Sundaram S; Chinnaiyan AM; Varambally S; D'Silva NJ
    Oncogene; 2011 Oct; 30(42):4339-49. PubMed ID: 21532618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
    Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
    Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
    Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
    Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
    Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
    PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.
    Selvarajan V; Osato M; Nah GSS; Yan J; Chung TH; Voon DC; Ito Y; Ham MF; Salto-Tellez M; Shimizu N; Choo SN; Fan S; Chng WJ; Ng SB
    Leukemia; 2017 Oct; 31(10):2219-2227. PubMed ID: 28119527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
    Li B; Chng WJ
    J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.